Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 3, 2002, Pages 808-812

  Piddock, Laura J V ^a   Johnson, Maggie M ^a   Simjee, S ^a   Pumbwe, L ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACRIFLAVINE; CHLORAMPHENICOL; CIPROFLOXACIN; CLINAFLOXACIN; ETHIDIUM BROMIDE; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; SITAFLOXACIN; SPARFLOXACIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; GENE EXPRESSION; GENE SEQUENCE; GYRA GENE; GYRB GENE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORTHERN BLOTTING; PARC GENE; PARE GENE; PHENOTYPE; PRIORITY JOURNAL; PRMA GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; BACTERIAL PROTEINS; BLOTTING, NORTHERN; CIPROFLOXACIN; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, MICROBIAL; MICROBIAL SENSITIVITY TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, BACTERIAL; STREPTOCOCCUS PNEUMONIAE;

EID: 0036168493     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.3.808-812.2002     Document Type: Article

References (16)

1. Determination of minimum inhibitory concentrations
2. Apparent involvement of a multidrug transporter in the fluoroquinolone resistance of Streptococcus pneumoniae
3. The effect of reserpine, an inhibitor of multi-drug efflux pumps, on the in vitro susceptibilities of fluoroquinolone-resistant strains of Streptococcus pneumoniae to norfloxacin
4. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae
5. A rapid and versatile method to synthesise internal standards for competitive PCR
6. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae
7. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA
8. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptocococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season
9. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and pare loci
10. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: Role in fluoroquinolone resistance
11. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
12. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract
13. Non-gyrA -mediated ciprofloxacin resistance in laboratory mutants of Streptococcus pneumoniae
14. Two efflux systems expressed simultaneously in multidrug-resistant Pseudomonas aeruginosa
15. Complete genome sequence of a virulent isolate of Streptococcus pneumoniae
16. Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae